Alcohol Dependence Clinical Trial
— INTRAOfficial title:
Learning to Resist the Urge: Inhibition Training in Abstinent Patients With Alcohol Use Disorders. A Randomized Controlled Trial
Verified date | May 2022 |
Source | University of Bern |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to investigate the effects of a short computerized training as a therapeutic add-on to standard therapy in patients with alcohol-use disorder.
Status | Completed |
Enrollment | 242 |
Est. completion date | July 2020 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 18 Years |
Eligibility | Inclusion Criteria: - Abstinent patients with an alcohol use disorder in the 12-week inpatient program of the Clinic Südhang or the Forel Clinic, - Abstained from alcohol for at least 4 weeks (in relation to timepoint when training will start), - Informed Consent as documented by signature. Exclusion Criteria: - Other main psychiatric diagnosis than alcohol use disorder (comorbidity is allowed if the alcohol use disorder is to be considered the main diagnosis), - other severe substance use disorder (except nicotine), even as secondary diagnosis - Neurocognitive problems (e.g. Korsakoff syndrome), - Current medical conditions excluding participation (e.g. acute infectious disease), - Inability to read and understand the participant's information, - Enrolment of the investigator, his/her family members, employees and other dependent persons. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Forel Klinik | Ellikon | |
Switzerland | Klinik Südhang | Kirchlindach | |
Switzerland | Psychiatric Center Muensingen | Münsingen |
Lead Sponsor | Collaborator |
---|---|
University of Bern | Clinic Südhang, Forel Clinic, Psychiatric Center Muensingen |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent days of abstinence 3-months follow-up. | Percentage of abstinent days in 3-months follow-up. This will be measured with the timeline follow back (TFB), which is a validated procedure to aid recall of past drinking and evaluates information about drinking behavior. | 3-months follow-up | |
Primary | Inhibition Go/NoGo | Inhibitory control as assessed with a Go/NoGo task. | Post training, i.e. between 1 and 7 days after completion of the last (i.e. the 6th) training session | |
Primary | Neurophysiology of inhibitory Control (Go/NoGo) | Neurophysiological correlates of inhibitory control as assessed with EEG-measurement during the Go-NOGo-task. ERPs in response to NoGo-Stimuli will be calculated and the N2/p3-complex will be analyzed | Post training, i.e. between 1 and 7 days after completion of the last (i.e. the 6th) training session | |
Primary | Implicit associations (IAT) | Implicit associations as assessed with an alcohol-related implicit association task (IAT) | Post training, i.e. between 1 and 7 days after completion of the last (i.e. the 6th) training session | |
Primary | Heavy drinking days in 3 months follow-up | in 3-months follow-up. This will be measured Heavy drinking days in 3 months follow-up, measured with the timeline follow back (TFB), which is a validated procedure to aid recall of past drinking and evaluates information about drinking behavior. | 3 months follow-up | |
Secondary | Abstinence related self-efficacy | Self efficacy will be assessed with the alcohol abstinence self-efficacy scale (AASE). | Post-training (i.e. between 1 and 7 days after completion of the training session); discharge, 3-, 6- and 12-months follow-up | |
Secondary | Craving | Craving will be measured with the German version of the Obsessive compulsive drinking scale (OCDS-G). | Post-training (i.e. between 1 and 7 days after completion of the last training session); discharge, 3-, 6- and 12-months follow-up | |
Secondary | Time to first drink | 3-, 6- and 12-months follow-up | ||
Secondary | Percent heavy drinking days | 3-, 6- and 12-months follow-up | ||
Secondary | Inhibition (SST) | Inhibitory control will be assessed with a Stop-Signal task | Post-training; i.e. between 1 and 7 days after completion of the last (i.e. the 6th) training session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |